Bivatuzumab mertansine

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Bivatuzumab mertansine
Mertansine mab structure.svg
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetCD44 v6
Clinical data
ATC code
  • none
Identifiers
ChemSpider
  • none
 ☒N☑Y (what is this?)  (verify)

Bivatuzumab mertansine is a combination of bivatuzumab, a humanized monoclonal antibody, and mertansine, a cytotoxic agent. It is designed for the treatment of squamous cell carcinoma.[1]

References[edit]

  1. ^ Tijink, BM; Buter, J; De Bree, R; Giaccone, G; Lang, MS; Staab, A; Leemans, CR; Van Dongen, GA (2006). "A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus". Clinical Cancer Research. 12 (20 Pt 1): 6064–72. doi:10.1158/1078-0432.CCR-06-0910. PMID 17062682.